Clarify Medical Raises $18M in Series A Funding

光治疗系统供应商Claify Medical获1800万美元A轮融资,用于慢性皮肤病研究

2019-11-08 11:29:25 Finsmes

本文共679个字,阅读需2分钟

Clarify Medical, a San Diego, CA-based provider of a home light therapy system for the treatment and monitoring of patients with chronic skin conditions, closed an $18M Series A financing. Backers included H.I.G. BioHealth Partners, 7wire Ventures, SV Health Investors, and Bluestem Capital. In conjunction with the funding, Michael Wasserman, Managing Director of H.I.G. BioHealth Partners; Robert Garber, Partner at 7wire Ventures; and Paul LaViolette, Managing Partner and Chief Operating Officer of SV Health Investors, will join Clarify Medical’s board of directors. The company intends to use the funds for the commercialization and further development of its therapy system. Led by George Mahaffey, President & CEO, Clarify Medical medical device company focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Its Clarify System, which has been cleared by the FDA, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is a connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of targeted narrowband UVB (NB-UVB) light therapy. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision and achieve clinical efficacy in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.
Claify Medical 是一家总部位于圣地亚哥的家庭光治疗系统供应商,为治疗和监测慢性皮肤病患者提供服务,该公司关闭了一笔1800万美元的 A 系列融资。 支持者包括 H.I.G . BioHealth Partners 、7wire Ventures 、 SV Health Investors 和 Bluestem Capital 。结合资金, H.I.G . BioHealth Partners 董事总经理 Michael Wasserman 、7wire Ventures 合伙人 Robert Garber 和 SV Health Investors 董事总经理兼首席运营官 Paul LaViolette 将加入 Clarity Medical 董事会。 公司拟将该资金用于其治疗系统的商业化和进一步开发。 在总裁兼首席执行官 George Mahafey 的带领下, Claify 医疗器械公司致力于开发创新的技术、产品和服务,以改善慢性病患者的护理。其澄清系统已经 FDA 批准,适用于所有皮肤类型( I-VI )上的银屑病、白癜风、特应性皮炎(湿疹)、脂溢性皮炎、白癜风等皮肤病的局部光治疗。它是一种连接的光治疗系统,使用患者自己的智能手机( iOS 或 Android )上的应用程序来管理定向窄带 UVB ( NB-UVB )光治疗的剂量、频率和持续时间。 治疗养生法由患者的医生处方,但由澄清系统进行监测和控制,使患者能够进行临床精确的治疗,并实现临床疗效,方便他们的家。 连接系统监控剂量、依从性、依从性、病人进展和满意度。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文